What Analysts Are Saying About Ardelyx Stock
Portfolio Pulse from Benzinga Insights
Ardelyx (NASDAQ:ARDX) has received diverse analyst ratings in the last three months, with 4 analysts offering views ranging from bullish to bearish. The average 12-month price target is $11.75, up 11.9% from the previous $10.50, with a high estimate of $15.00 and a low of $9.00. Analysts from Raymond James and HC Wainwright & Co. have raised their price targets, while Wedbush maintains its target. Ardelyx is a biotech company with a focus on gastrointestinal and cardiorenal diseases, and its lead product is tenapanor. The company has shown a revenue growth rate of 1030.99% as of September 30, 2023, a net margin of 11.76%, an ROE of 4.22%, an ROA of 2.65%, and a low debt-to-equity ratio of 0.18.
January 09, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ardelyx has received positive analyst ratings with raised price targets, indicating a bullish sentiment. The company's strong financial performance and significant revenue growth are likely to positively influence investor confidence and the stock price.
The increase in the average price target to $11.75, along with strong financial indicators such as a high revenue growth rate and solid profitability metrics, suggest a positive short-term impact on ARDX's stock price. Analyst upgrades typically lead to increased investor confidence and can drive stock prices upward.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100